Pipeline

• ARC 100 (Formerly TPI 287)
  
  • Novel compound - new chemical entity
  • Validated mechanism of action
  • Both oral and IV formulation in development
  • Safety and efficacy improved over existing therapy
  • Effective in chemotherapy resistant tumors